Tycho B.
- Country
- Spain
- Department
- Hematology
Research Overview
- Phase 1 First-in-Human Study of JNJ-95566692 in Participants with Non-Hodgkin Lymphoma
- Phase I Study to Evaluate the Safety of STAb-T19 Genetically Modified T Cells Secreting αCD19xαCD3 Bispecific Antibodies in Patients with Malignant B-cell Neoplasms
- Phase 1 Study of JNJ-95804306 in Relapsed or Refractory AML, CLL, Higher‑Risk MDS, and SLL
Data & Insights
Has run more than one trial at 25 of 167 partner sites.
Specializations
Lymphoma Treatment Innovation
This investigator specializes in developing novel therapeutic approaches for diffuse large B-cell lymphoma (DLBCL), with particular focus on both newly diagnosed and relapsed/refractory cases.
- First-line DLBCL therapy optimization
- Novel combination treatments
- High-risk DLBCL management
The research encompasses innovative therapeutic combinations including targeted antibodies and immunomodulatory agents.
Chronic Lymphocytic Disorders
The investigator conducts research in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), focusing on advanced treatment strategies for previously treated patients.
- Novel therapeutic combinations
- Treatment-resistant disease
- Targeted therapy approaches
Their work explores innovative treatment pathways for patients who have undergone prior therapies.
B-Cell Lymphoma Research
The investigator studies B-cell non-Hodgkin's lymphoma with emphasis on developing new therapeutic strategies for relapsed and refractory cases.
- Immunotherapy development
- Multi-drug combinations
- Refractory disease management
Their research includes evaluation of novel antibody-based therapies and combination approaches for resistant disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.